<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antibiotic regimens for treatment of &lt;EM&gt;Babesia microti&lt;/EM&gt; disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antibiotic regimens for treatment of <em>Babesia microti</em> disease</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antibiotic regimens for treatment of <em>Babesia microti</em> disease</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">Disease severity</td> <td class="subtitle1">Adult dosing</td> <td class="subtitle1">Pediatric dosing</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Mild to moderate disease (ambulatory patients)*<sup>¶</sup><sup>Δ</sup></td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="3">Preferred regimen</td> <td>Azithromycin <ul class="decimal_heading"> <li>500 mg orally once on day 1, followed by</li> <li>250 mg orally once daily beginning on day 2</li> </ul> </td> <td>Azithromycin <ul class="decimal_heading"> <li>10 mg/kg orally once on day 1 (maximum 500 mg/dose), followed by</li> <li>5 mg/kg orally once daily beginning on day 2 (maximum 250 mg/dose)</li> </ul> </td> </tr> <tr> <td><strong>PLUS</strong></td> <td><strong>PLUS</strong></td> </tr> <tr class="divider_bottom"> <td>Atovaquone<sup>◊</sup> <ul class="decimal_heading"> <li>750 mg orally every 12 hours</li> </ul> </td> <td>Atovaquone<sup>◊</sup> <ul class="decimal_heading"> <li>20 mg/kg orally every 12 hours (maximum 750 mg/dose)</li> </ul> </td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="3">Alternative regimen<sup>§</sup></td> <td>Clindamycin <ul class="decimal_heading"> <li>600 mg orally every 8 hours</li> </ul> </td> <td>Clindamycin <ul class="decimal_heading"> <li>7 to 10 mg/kg orally every 6 to 8 hours (maximum 600 mg/dose)</li> </ul> </td> </tr> <tr> <td><strong>PLUS</strong></td> <td><strong>PLUS</strong></td> </tr> <tr class="divider_bottom"> <td>Quinine sulfate<sup>¥</sup> <ul class="decimal_heading"> <li>650 mg orally every 8 hours</li> </ul> </td> <td>Quinine sulfate<sup>¥</sup> <ul class="decimal_heading"> <li>8 mg/kg orally every 8 hours (maximum 650 mg/dose)</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle2_left" colspan="3">Severe acute disease (hospitalized patients): Initial management<sup>‡</sup></td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="3">Preferred regimen</td> <td>Azithromycin<sup>†</sup> <ul class="decimal_heading"> <li>500 mg IV once daily until symptoms abate, then transition to all-oral regimen (refer to 'Step-down therapy' below)</li> </ul> </td> <td>Azithromycin** <ul class="decimal_heading"> <li>10 mg/kg IV once daily (maximum 500 mg/dose) until symptoms abate, then transition to all-oral regimen (refer to 'Step-down therapy' below)</li> </ul> </td> </tr> <tr> <td><strong>PLUS</strong></td> <td><strong>PLUS</strong></td> </tr> <tr class="divider_bottom"> <td>Atovaquone<sup>◊</sup> <ul class="decimal_heading"> <li>750 mg orally every 12 hours</li> </ul> </td> <td>Atovaquone<sup>◊</sup> <ul class="decimal_heading"> <li>20 mg/kg orally every 12 hours (maximum 750 mg/dose)</li> </ul> </td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="3">Alternative regimen<sup>§</sup></td> <td>Clindamycin <ul class="decimal_heading"> <li>600 mg IV every 6 hours until symptoms abate, then transition to all-oral regimen (refer to 'Step-down therapy' below)</li> </ul> </td> <td>Clindamycin <ul class="decimal_heading"> <li>7 to 10 mg/kg IV every 6 to 8 hours (maximum 600 mg/dose) until symptoms abate, then transition to all-oral regimen (refer to 'Step-down therapy' below)</li> </ul> </td> </tr> <tr> <td><strong>PLUS</strong></td> <td><strong>PLUS</strong></td> </tr> <tr class="divider_bottom"> <td>Quinine sulfate<sup>¥</sup> <ul class="decimal_heading"> <li>650 mg orally every 8 hours</li> </ul> </td> <td>Quinine sulfate<sup>¥</sup> <ul class="decimal_heading"> <li>8 mg/kg orally every 8 hours (maximum 650 mg/dose)</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle2_left" colspan="3">Severe acute disease (hospitalized patients): Step-down therapy (eg, once symptoms have improved and parasitemia has declined)<sup>¶¶</sup></td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="3">Preferred regimen</td> <td>Azithromycin <ul class="decimal_heading"> <li>250 to 500 mg orally once daily</li> </ul> </td> <td>Azithromycin <ul class="decimal_heading"> <li>5 to 10 mg/kg orally once daily (maximum 500 mg/dose)</li> </ul> </td> </tr> <tr> <td><strong>PLUS</strong></td> <td><strong>PLUS</strong></td> </tr> <tr class="divider_bottom"> <td>Atovaquone<sup>◊</sup> <ul class="decimal_heading"> <li>750 mg orally every 12 hours</li> </ul> </td> <td>Atovaquone<sup>◊</sup> <ul class="decimal_heading"> <li>20 mg/kg orally every 12 hours (maximum 750 mg/dose)</li> </ul> </td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="3">Alternative regimen</td> <td>Clindamycin <ul class="decimal_heading"> <li>600 mg orally every 8 hours</li> </ul> </td> <td>Clindamycin <ul class="decimal_heading"> <li>7 to 10 mg/kg orally every 6 to 8 hours (maximum 600 mg/dose)</li> </ul> </td> </tr> <tr> <td><strong>PLUS</strong></td> <td><strong>PLUS</strong></td> </tr> <tr class="divider_bottom"> <td>Quinine sulfate<sup>¥</sup> <ul class="decimal_heading"> <li>650 mg orally every 8 hours</li> </ul> </td> <td>Quinine sulfate<sup>¥</sup> <ul class="decimal_heading"> <li>8 mg/kg orally every 8 hours (maximum 650 mg/dose)</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle2_left" colspan="3">Highly immunocompromised patients<sup>ΔΔ</sup></td> </tr> <tr> <td class="indent1"> </td> <td>Begin as summarized above for patients with severe acute disease, then continue with a step-down regimen once symptoms have improved and parasitemia has declined. When oral azithromycin is used, a higher dose (500 to 1000 mg orally once daily) may be administered. Highly immunocompromised patients should be treated for at least 6 consecutive weeks, including 2 final weeks during which parasites are no longer detected on peripheral blood smear.</td> <td> </td> </tr> </tbody></table></div><div class="graphic_footnotes">IV: intravenously.<br/>* Patients with mild to moderate disease are usually immunocompetent, have parasitemia &lt;4%, and do not require hospital admission.<br/>¶ The usual duration of therapy is 7 to 10 days. An extended course of therapy is needed when parasitemia and symptoms persist (refer to UpToDate text).<sup>[1-4]</sup><br/>Δ Immunocompromised patients with mild to moderate <em>B. microti</em> infection may be treated on an outpatient basis with close monitoring. Antimicrobial therapy consists of oral azithromycin (500 to 1000 mg orally per day) plus oral atovaquone (750 mg orally twice daily).<br/><font class="lozenge">◊</font> Atovaquone should be administered with a fatty meal.<br/>§ Clindamycin plus quinine should be used if parasitemia and symptoms fail to abate with use of the preferred regimen (atovaquone plus azithromycin) or for patients unable to take the preferred regimen.<br/>¥ The quinine doses listed are for the sulfate salt (which is the only quinine formulation available in the United States); 650 mg quinine sulfate is approximately equivalent to 542 mg quinine base and 8 mg/kg quinine sulfate is approximately equivalent to 6 mg/kg quinine base. In the United States, quinine sulfate is available as a 324 mg capsule; 2 capsules (648 mg quinine sulfate) is acceptable for adult dosing. Other countries may have different dosage forms and strengths.<br/>‡ Severe babesiosis often occurs in older and/or immunocompromised patients and is associated with parasitemia ≥4% (although it can occur with parasitemia &lt;4%). Exchange transfusion may be considered for patients with high-grade parasitemia (&gt;10%) and/or any one or more of the following: severe hemolytic anemia and/or severe pulmonary, renal, or hepatic compromise. Consultation with a transfusion services physician or hematologist, as well as an infectious diseases specialist, is strongly advised.<br/>† Azithromycin dose 1000 mg orally (given in combination with other antibiotics) has been used successfully for treatment of <em>B. microti</em> infection in immunocompromised patients. An initial one-time dose of azithromycin 1000 mg IV has been used for treatment of severe babesiosis but with very limited experience. While this IV dose has been shown to be safe, there are no published reports of the use of this dose for severe babesiosis. If azithromycin 1000 mg IV is used for initial treatment, subsequent IV doses should be reduced to 500 mg daily.<br/>** There have been no studies of pediatric IV azithromycin dosing for babesiosis.<br/>¶¶ For patients with severe disease, the total duration of therapy (eg, initial management plus step-down therapy) is typically 7 to 10 days. For immunocompromised patients, a higher dose of azithromycin (500 to 1000 mg orally daily) may be administered.<br/>ΔΔ Highly immunocompromised patients are at risk of relapse despite receiving standard therapy and include those who have received or are receiving rituximab (eg, for B cell lymphoma or an autoimmune disorder), are receiving other immunosuppressive regimens (eg, for solid organ or stem cell transplantation or malignancy), have malignancy and are asplenic, or have HIV infection with low CD4 T cell counts (AIDS).</div><div class="graphic_reference">References: 

<ol>
<li class="">Krause PJ, Auwarter PG, Bannuru RR, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. Clin Infect Dis 2021; 72:e49. </li>
<li class="">Corrigendum to: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. Clin Infect Dis 2021; ciab275.</li>
<li>Vannier E, Krause PJ. Human babesiosis. N Engl J Med 2012; 366:2397.</li>
<li>Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med 2000; 343:1454.</li></ol></div><div id="graphicVersion">Graphic 114688 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
